kaiyun(Öйú)¹Ù·½ÍøÕ¾-¿ªÔÆÌåÓý¹Ù·½Èë¿Ú



MK3102

MK3102 £¨¶©»õÒÔCAS±àÂë»òÓ¢ÎÄÃû³ÆÎª×¼£©

DPP-4ÒÖÖÆ¼Á£¬Omarigliptin(MK-3102)ÊÇDPP4¸ßЧѡÔñÐÔÒÖÖÆ¼Á£¬IC50ֵΪ1.6nM¡£
MedBioÌṩµÄËùÓвúÆ·½öÓÃÓÚ¿ÆÑеȷÇÒ½ÁÆÓÃ;£¬·ÇÒ©Æ·²»¿ÉʳÓ㬲»¿ÉÓÃÓÚÈËÌå»ò¶¯ÎïµÄÁÙ´²Õï¶ÏºÍÖÎÁÆ,ÎÒÃDz»Îª¸öÈËÌṩ²úÆ·¼°·þÎñ¡£ÈçÄúÐèÒª²úÆ·COAµÈ×ÊÁÏ£¬¿ÉÖÁÏ·½¡°ÖÊÁ¿¿ØÖÆ¡±ÖÐÏÂÔØ
±àºÅ£ºMED18532
·Ö×Óʽ£ºC17H20F2N4O3S
CASºÅ£º1226781-44-7
·Ö×ÓÁ¿£º398.43
ÉêÇëÊÔÓÃ
»õºÅ Æ·ÅÆ ¹æ¸ñ ´¿¶È/º¬Á¿ ±ê×¼¼Û ÓÅ»Ý¼Û ¿â´æ»õÆÚ ÊýÁ¿ ¹ºÂò
MED18532-5mg MedBio 5mg ¡Ý98% ?1589.00 µÇ¼ºó¿É¼û
MED18532-10mg MedBio 10mg ¡Ý98% ?2389.00 µÇ¼ºó¿É¼û
MED18532-50mg MedBio 50mg ¡Ý98% ?6389.00 µÇ¼ºó¿É¼û
ÖÐÎÄÃû³Æ£º MK£­3012
ÖÐÎıðÃû£º (2R,3S,5R)-2-(2,5-¶þ·ú±½»ù)-5-(2-(¼×»ù»Çõ£»ù)ßÁ¿©²¢[3,4-c]ßÁßò-5(2H,4H,6H)-»ù)ËÄÇâ-2H-ßÁà«-3-°·;Omarigliptin(MK-3102) ÒÖÖÆ¼Á;°Â¸ñÁÐÍ¡;°Â¸ñÁÐÍ¡£¨MK-3102£©;°Â¸ñÁÐÍ¡ÔÓÖÊ;°ÂÂê¸ñÁÐÍ¡;(2R,3S,5R)-2-(2,5-¶þ·ú±½»ù)-5-[2-(¼×»ù»Çõ£»ù)-2,6-¶þÇâßÁ¿©²¢[3,4-c]ßÁßò-5(4H)-»ù]ËÄÇâ-2H-ßÁà«-3-°·
Ó¢ÎÄÃû³Æ£º MK3102
Ó¢ÎıðÃû£º MK£­3012;(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine;(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)oxan-3-amine;(2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3...;MK-3102;Omarigliptin;Omarigliptin (MK3102);(2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-tetrahydro-2H-pyran-3-amine;MK3102;UNII-CVP59Q4JE1
CASºÅ£º 1226781-44-7
·Ö×Óʽ£º C17H20F2N4O3S
·Ö×ÓÁ¿£º 398.43
DPP-4ÒÖÖÆ¼Á£¬Omarigliptin(MK-3102)ÊÇDPP4¸ßЧѡÔñÐÔÒÖÖÆ¼Á£¬IC50ֵΪ1.6nM¡£
ËÑË÷Öʼ챨¸æ(COA)
Ïà¹Ø²úÆ·
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿